PROK Stock Price, ProKidney Corp. Quote, Chart

Market Summary

USD4.05+0.26

Delayed

6.86%

PROK Alerts

1 major insider sales recently.

PROK Stock Price

View Fullscreen

PROK RSI Chart

PROK Valuation

Market Cap

271.9M

Price/Earnings (Trailing)

-5.72

Price/Sales (Trailing)

12.57

EV/EBITDA

-1.5

Price/Free Cashflow

-2.05

PROK Price/Sales (Trailing)

PROK Profitability

EBT Margin

-596.90%

Return on Equity

4.33%

Return on Assets

-12.25%

Free Cashflow Yield

-48.88%

PROK Fundamentals

PROK Revenue

Revenue (TTM)

21.6M

Rev. Growth (Yr)

-8.57%

Rev. Growth (Qtr)

-8.28%

PROK Earnings

Earnings (TTM)

-47.5M

Earnings Growth (Yr)

4.27%

Earnings Growth (Qtr)

-546.07%

Breaking Down PROK Revenue

Last 7 days

44.1%

Last 30 days

42.6%

Last 90 days

158.0%

How does PROK drawdown profile look like?

PROK Financial Health

Current Ratio

17.62

PROK Investor Care

Shares Dilution (1Y)

9.09%

Diluted EPS (TTM)

-0.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	21.6M	0	0	0
2023	11.6M	17.2M	21.2M	22.1M
2022	0	0	4.8M	6.0M
2021	0	1.2M	2.4M	3.6M
2020	0	0	0	43.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ProKidney Corp.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	weber darin j.	sold	-41,315	2.5134	-16,438	svp of regulatory development
Apr 18, 2024	weber darin j.	sold	-2,028	2.535	-800	svp of regulatory development
Apr 16, 2024	weber darin j.	sold	-43,095	2.5	-17,238	svp of regulatory development
Apr 12, 2024	weber darin j.	sold	-145,498	1.73	-84,103	svp of regulatory development
Apr 01, 2024	weber darin j.	sold	-507	1.69	-300	svp of regulatory development
Feb 05, 2024	girolamo todd c	acquired	-	-	81,928	chief legal officer
Feb 05, 2024	legorreta pablo g.	acquired	-	-	748,952	-
Feb 05, 2024	legorreta pablo g.	sold	-	-	-748,952	-
Feb 05, 2024	weber darin j.	acquired	-	-	137,073	svp of regulatory development
Nov 19, 2023	palihapitiya chamath	sold	-9,498,580	1.309	-7,256,370	-

Which funds bought or sold PROK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	45.92	38,515	150,349	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-5,765	7,419	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	30.91	13,805	80,792	-%
May 15, 2024	Royal Bank of Canada	reduced	-84.01	-22,000	5,000	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-58.29	-16,019	9,997	-%
May 15, 2024	DEUTSCHE BANK AG\	reduced	-44.19	-2,182	2,309	-%
May 15, 2024	STATE STREET CORP	reduced	-3.95	-201,014	1,545,860	-%
May 15, 2024	MORGAN STANLEY	reduced	-7.77	-2,995,260	16,935,800	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	-1,000	18,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-33.04	-446,416	718,897	-%

Are Funds Buying or Selling PROK?

Are funds buying PROK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PROK

No. of Funds

PROK Alerts

1 major insider sales recently.

Unveiling ProKidney Corp.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	suvretta capital management, llc	5.8%	3,867,847	SC 13G/A
Feb 09, 2024	morgan stanley	16.1%	10,775,670	SC 13G/A
Feb 06, 2024	tolerantia, llc	37.6%	88,639,961	SC 13D/A
Nov 20, 2023	palihapitiya chamath	4.5%	3e+06	SC 13D/A
Nov 06, 2023	palihapitiya chamath	17.6%	11,795,700	SC 13D/A
Nov 02, 2023	tolerantia, llc	38.0%	89,388,913	SC 13D
Oct 27, 2023	palihapitiya chamath	20.4%	12,592,500	SC 13D/A
Oct 19, 2023	palihapitiya chamath	21.7%	13,361,473	SC 13D/A
Feb 10, 2023	morgan stanley	17.8%	10,934,182	SC 13G/A

Recent SEC filings of ProKidney Corp.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 23, 2024	4	Insider Trading
Apr 18, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	4	Insider Trading

ProKidney Corp. News

Latest updates

ProKidney Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3	2021Q2	2020Q4
Revenue	-8.3%	4,843,000	5,280,000	5,541,000	5,965,000	5,297,000	4,402,000	1,581,000	1,054,667	528,333	2,000	-
Operating Expenses	65.5%	40,076,000	24,210,000	46,617,000	39,819,000	40,876,000	30,235,000	35,572,000	13,709,000	17,081,000	12,717,000	-
S&GA Expenses	-100.0%	-	1,682,000	14,419,000	13,455,000	15,259,000	9,345,000	14,440,000	3,024,000	2,339,000	1,748,000	-
R&D Expenses	20.9%	27,233,000	22,528,000	32,198,000	26,364,000	25,617,000	20,890,000	21,132,000	10,685,000	14,742,000	10,969,000	-
EBITDA Margin	-1.6%	-5.78	-5.69	-6.29	-7.33	-9.77	-24.14	-27.54	-14.73	-10.76	-21.13	-605
Interest Expenses	-33.3%	2,000	3,000	2,000	4,000	3,000	-428,000	29,000	-500	1,000	-	-
Income Taxes	-96.5%	98,000	2,791,000	913,000	965,000	1,327,000	-1,262,000	-75,000	98,000	-60,000	10,000	-
Earnings Before Taxes	-86.1%	-35,235,000	-18,933,000	-41,078,000	-33,858,000	-35,582,000	-25,835,000	-34,020,000	-13,708,000	-17,082,000	-12,715,000	-
EBT Margin	-1.8%	-5.97	-5.86	-6.43	-7.50	-10.02	-24.61	-28.18	-15.28	-11.15	-21.92	-627
Net Income	-546.1%	-35,333,000	7,921,000	-10,984,000	-9,118,000	-36,909,000	-24,573,000	-33,945,000	-13,670,000	-17,142,000	-12,725,000	-
Net Income Margin	1.2%	-2.20	-2.22	-3.85	-6.06	-10.12	-24.76	-28.62	-15.29	-11.06	-21.73	-622
Free Cashflow	-32.1%	-35,606,000	-26,956,000	-51,716,000	-18,616,000	-26,978,000	-16,067,000	-23,158,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-7.8%	388	421	452	484	495	518	532	54.00	54.00	40.00	251	134	17.00
Current Assets	-9.1%	340	374	406	466	480	505	519	34.00	35.00	27.00	1.00	0.00	6.00
Cash Equivalents	39.1%	84.00	61.00	191	244	272	490	506	22.00	30.00	21.00	4.00	12.00	5.00
Net PPE	-0.5%	42.00	42.00	43.00	15.00	12.00	11.00	11.00	11.00	11.00	11.00	-	-	9.00
Liabilities	-15.4%	25.00	29.00	24.00	27.00	14.00	13.00	12.00	16.00	13.00	13.00	8.00	-	-
Current Liabilities	-22.9%	19.00	25.00	21.00	24.00	11.00	11.00	10.00	46.00	32.00	12.00	0.00	1.00	6.00
Shareholder's Equity	0.7%	-1,096	-1,103	-	-	-1,601	-1,096	-	7.00	20.00	27.00	10.00	16.00	10.00
Retained Earnings	-0.8%	-1,149	-1,139	-1,133	-1,353	-1,623	-1,104	-1,097	-251	-229	-161	-6.32	-6.06	-106
Additional Paid-In Capital	47.1%	53.00	36.00	41.00	31.00	22.00	7.00	1.00	-	-	-	-	0.00	-
Shares Outstanding	-	-	-	174	174	173	172	171	187	187	187	157	145	115
Float	-	-	-	-	689	-	-	-	248,750	-	-	-	251	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	-36.5%	-34,646	-25,384	-23,777	-14,916	-25,992	-15,761	-22,843	-23,026	-15,459	-12,990	-18,214	-19.84	-7,256	-
Share Based Compensation	220.5%	7,679	-6,370	12,994	11,202	13,020	8,940	4,844	8,001	52,684	175	174	175	175	-
Cashflow From Investing	160.9%	58,399	-95,844	-28,374	-13,153	-192,612	-306	-207	-386	-839	-	-1,259	-2,004	-1,389	-
Cashflow From Financing	99.9%	-13.00	-9,512	-13.00	-13.00	-13.00	-8.00	507,495	15,492	25,542	-28.18	21,242	243	19,993	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PROK Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - Unaudited - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 27,233	$ 25,617
General and administrative	12,843	15,259
Total operating expenses	40,076	40,876
Operating loss	(40,076)	(40,876)
Interest income	4,843	5,297
Interest expense	(2)	(3)
Net loss before income taxes	(35,235)	(35,582)
Income tax expense	98	1,327
Net loss before noncontrolling interest	(35,333)	(36,909)
Net loss attributable to noncontrolling interest	(25,841)	(27,244)
Net loss available to Class A ordinary shareholders	(9,492)	(9,665)
Common Class A [Member]
Operating expenses
Net loss available to Class A ordinary shareholders	$ (9,492)	$ (9,665)
Weighted Average Number of Shares Outstanding, Basic	60,951,721	61,540,231
Weighted Average Number Of Shares Outstanding, Diluted	60,951,721	61,540,231
Net loss per share attributable to Class A ordinary shares, Basic	$ (0.16)	$ (0.16)
Net loss per share attributable to Class A ordinary shares, Diluted	$ (0.16)	$ (0.16)

PROK Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - Unaudited - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 84,389	$ 60,649
Marketable securities	244,609	302,301
Interest receivable	1,903	1,375
Prepaid assets	3,106	3,399
Prepaid clinical	6,151	6,413
Other current assets	0	9
Total current assets	340,158	374,146
Fixed assets, net	41,937	42,143
Right of use assets, net	5,668	4,263
Total assets	387,763	420,552
Current liabilities
Accounts payable	3,376	5,098
Lease liabilities	1,092	803
Accrued expenses and other	13,263	17,665
Income taxes payable	1,570	1,472
Total current liabilities	19,301	25,038
Income tax payable, net of current portion	568	568
Lease liabilities, net of current portion	4,859	3,610
Total liabilities	24,728	29,216
Commitments and contingencies
Redeemable noncontrolling interest	1,459,097	1,494,732
Shareholders' deficit
Additional paid-in capital	53,114	36,114
Accumulated other comprehensive (loss) gain	(44)	130
Accumulated deficit	(1,149,155)	(1,139,663)
Total shareholders' deficit	(1,096,062)	(1,103,396)
Total liabilities and shareholders' deficit	387,763	420,552
Common Class A [Member]
Shareholders' deficit
Common stock value	6	6
Common Class B [Member]
Shareholders' deficit
Common stock value	$ 17	$ 17

About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

CEO	Dr. Timothy A. Bertram D.V.M., Ph.D.
WEBSITE	prokidney.com
INDUSTRY	Biotechnology
EMPLOYEES	87

ProKidney Corp. Frequently Asked Questions

What is the ticker symbol for ProKidney Corp.? What does PROK stand for in stocks?

PROK is the stock ticker symbol of ProKidney Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ProKidney Corp. (PROK)?

As of Fri May 17 2024, market cap of ProKidney Corp. is 271.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PROK stock?

You can check PROK's fair value in chart for subscribers.

What is the fair value of PROK stock?

You can check PROK's fair value in chart for subscribers. The fair value of ProKidney Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ProKidney Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PROK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ProKidney Corp. a good stock to buy?

The fair value guage provides a quick view whether PROK is over valued or under valued. Whether ProKidney Corp. is cheap or expensive depends on the assumptions which impact ProKidney Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PROK.

What is ProKidney Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PROK's PE ratio (Price to Earnings) is -5.72 and Price to Sales (PS) ratio is 12.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PROK PE ratio will change depending on the future growth rate expectations of investors.